Peak neutralizing and cross-neutralizing antibody levels to human papillomavirus types 6/16/18/31/33/45/52/58 induced by bivalent and quadrivalent HPV vaccines

We performed an independent comparison of neutralizing and cross-neutralizing antibody (ab) levels seven months after initiation of three-dose, six-month vaccination schedules with the bivalent and quadrivalent human papillomavirus (HPV) vaccines in adolescent Finnish and Indian females, respectivel...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:NPJ Vaccines
Autores principales: Mariz, Filipe Colaço, Bender, Noemi, Anantharaman, Devasena, Basu, Partha, Bhatla, Neerja, Pillai, Madhavan Radhakrisna, Prabhu, Priya R., Sankaranarayanan, Rengaswamy, Eriksson, Tiina, Pawlita, Michael, Prager, Kristina, Sehr, Peter, Waterboer, Tim, Müller, Martin, Lehtinen, Matti
Formato: Artigo
Lenguaje:Inglês
Publicado: Nature Publishing Group UK 2020
Materias:
Brief Communication
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7021830/
https://ncbi.nlm.nih.gov/pubmed/32128255
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41541-020-0165-x
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares